Later, studies combining more advanced molecular genetic analyses in breast cancer, such as HER2 fluorescence in situ hybridisation (FISH) and comparative genomic hybridisation (CGH) strategies to explore subclonal chromosomal gains and losses also reported substantial ITH [30, 31, 32, 33]. This evidence concerns the gene ERBB2 and breast cancer.